Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Invasive measurement of hepatic venous pressure gradient before resection of hepatocellular carcinoma

P. Hříbek, J. Klasová, T. Tůma, J. Pudil, K. Menclová, T. Mačinga, E. Kubala, P. Urbánek

. 2023 ; 9 (3) : 236-242. [pub] 20230823

Status not-indexed Language English Country Poland

Document type Journal Article

AIM OF THE STUDY: To evaluate the role of hepatic venous pressure gradient (HVPG) measurement in patients with resectable hepatocellular carcinoma (HCC) we describe our experience with the procedure as part of our hospital standard preoperative algorithm. We present our protocol for this situation, the HVPG measurement procedure, and the results of our cohort. MATERIAL AND METHODS: We performed a retrospective statistical analysis of all patients who underwent planned hepatic resection for HCC with HVPG measurement between 1/2016 and 1/2023. The cohort included 35 patients (30 males, mean age 69.5 years) who underwent HVPG measurement before liver resection for HCC. RESULTS: The success rate of measurement was 91.4%, with serious complications in 2.9% of cases. Due to the clinically significant portal hypertension (CSPH) 31.3% of patients were rejected for resection. Seventeen patients with excluded CSPH underwent resection with one case of a postoperative liver event, liver decompensation, representing 5.9% of them. One patient (5.9%) had a complicated postoperative course with fasciitis. None of the patients who underwent resection (88.2%) was readmitted to the hospital due to surgical complications or a liver event during 90 days of follow-up, and no death was reported. The median overall survival (OS) in the resected subgroup was 70 months (95% CI: 52-86), and in patients rejected for surgery (resection and transplantation) 35 months (95% CI: 13-48). CONCLUSIONS: HVPG measurement is the gold standard for the quantification of portal hypertension. Hepatic vein catheterization is invasive, but a safe procedure, with a clear impact on the management of resectable HCC.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23022861
003      
CZ-PrNML
005      
20240529091920.0
007      
ta
008      
240105s2023 pl f 000 0|eng||
009      
AR
024    7_
$a 10.5114/ceh.2023.130662 $2 doi
035    __
$a (PubMed)37790686
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Hříbek, Petr $u Department of Medicine, 1 Faculty of Medicine, Charles University and Military University Hospital Prague, Praha, Czech Republic $u Department of Medicine, Faculty of Military Health Sciences, University of Defense, Hradec Králové, Czech Republic
245    10
$a Invasive measurement of hepatic venous pressure gradient before resection of hepatocellular carcinoma / $c P. Hříbek, J. Klasová, T. Tůma, J. Pudil, K. Menclová, T. Mačinga, E. Kubala, P. Urbánek
520    9_
$a AIM OF THE STUDY: To evaluate the role of hepatic venous pressure gradient (HVPG) measurement in patients with resectable hepatocellular carcinoma (HCC) we describe our experience with the procedure as part of our hospital standard preoperative algorithm. We present our protocol for this situation, the HVPG measurement procedure, and the results of our cohort. MATERIAL AND METHODS: We performed a retrospective statistical analysis of all patients who underwent planned hepatic resection for HCC with HVPG measurement between 1/2016 and 1/2023. The cohort included 35 patients (30 males, mean age 69.5 years) who underwent HVPG measurement before liver resection for HCC. RESULTS: The success rate of measurement was 91.4%, with serious complications in 2.9% of cases. Due to the clinically significant portal hypertension (CSPH) 31.3% of patients were rejected for resection. Seventeen patients with excluded CSPH underwent resection with one case of a postoperative liver event, liver decompensation, representing 5.9% of them. One patient (5.9%) had a complicated postoperative course with fasciitis. None of the patients who underwent resection (88.2%) was readmitted to the hospital due to surgical complications or a liver event during 90 days of follow-up, and no death was reported. The median overall survival (OS) in the resected subgroup was 70 months (95% CI: 52-86), and in patients rejected for surgery (resection and transplantation) 35 months (95% CI: 13-48). CONCLUSIONS: HVPG measurement is the gold standard for the quantification of portal hypertension. Hepatic vein catheterization is invasive, but a safe procedure, with a clear impact on the management of resectable HCC.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Klasová, Johana $u Department of Medicine, 1 Faculty of Medicine, Charles University and Military University Hospital Prague, Praha, Czech Republic
700    1_
$a Tůma, Tomáš $u Department of Medicine, Faculty of Military Health Sciences, University of Defense, Hradec Králové, Czech Republic $u Department of Radiodiagnostic, Military University Hospital Prague, Praha, Czech Republic
700    1_
$a Pudil, Jiří $u Department of Surgery, 2 Faculty of Medicine, Charles University and Military University Hospital Prague, Praha, Czech Republic
700    1_
$a Menclová, Kateřina $u Department of Surgery, 2 Faculty of Medicine, Charles University and Military University Hospital Prague, Praha, Czech Republic
700    1_
$a Mačinga, Tomáš $u Clinic of Oncology, 1 Faculty of Medicine, Charles University, Thomayer University Hospital Prague, Praha, Czech Republic $7 xx0317763
700    1_
$a Kubala, Eugen $u Clinic of Oncology, 1 Faculty of Medicine, Charles University, Thomayer University Hospital Prague, Praha, Czech Republic
700    1_
$a Urbánek, Petr $u Department of Medicine, 1 Faculty of Medicine, Charles University and Military University Hospital Prague, Praha, Czech Republic
773    0_
$w MED00203266 $t Clinical and experimental hepatology $x 2392-1099 $g Roč. 9, č. 3 (2023), s. 236-242
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37790686 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240105 $b ABA008
991    __
$a 20240529091916 $b ABA008
999    __
$a ok $b bmc $g 2036426 $s 1209306
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 9 $c 3 $d 236-242 $e 20230823 $i 2392-1099 $m Clinical and experimental hepatology $n Clin Exp Hepatol $x MED00203266
LZP    __
$a Pubmed-20240105

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...